| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1033058988 |
| P356 | DOI | 10.1038/KI.1989.43 |
| P698 | PubMed publication ID | 2709674 |
| P2093 | author name string | J Ruiz | |
| M A Katz | |||
| D A Ogden | |||
| D B Van Wyck | |||
| L F Kirlin | |||
| J C Stivelman | |||
| P2860 | cites work | Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial | Q34182887 |
| Iron balance in hemodialysis patients | Q44056257 | ||
| Iron overload and mobilization in long-term hemodialysis patients | Q69414097 | ||
| Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin | Q71079461 | ||
| Hepatic hemosiderosis in maintenance hemodialysis (MHD) patients | Q71181939 | ||
| The rationale for treating iron deficiency anemia | Q71289414 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 712-716 | |
| P577 | publication date | 1989-02-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Iron status in patients receiving erythropoietin for dialysis-associated anemia | |
| P478 | volume | 35 |
| Q73355674 | A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease |
| Q74823001 | A cost-effectiveness analysis of epoetin usage for patients with AIDS |
| Q28296498 | A randomized controlled study of iron supplementation in patients treated with erythropoietin |
| Q70607398 | A serial study of the erythropoietic response to thermal injury |
| Q79368573 | Additional effect of hyperparathyroidism on inflammatory status and rHuEPO requirements in hemodialysis patients |
| Q72179877 | Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency |
| Q72326281 | Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use? |
| Q43971416 | Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy |
| Q37593694 | Comparison of short-term efficacy of iron sucrose with those of ferric chloride in hemodialysis patients: An open-label study |
| Q34450659 | Considerations for optimal iron use for anemia due to chronic kidney disease |
| Q36115904 | Controversies in determination of epoetin (recombinant human erythropoietin) dosages |
| Q74823640 | Costs of epoetin in patients with AIDS |
| Q35820499 | Detection of functional iron deficiency during erythropoietin treatment: a new approach |
| Q71076813 | Diagnosis of iron deficiency in dialysis patients |
| Q70758585 | Early dosing practices and effectiveness of recombinant human erythropoietin |
| Q55162344 | Elevated Neutrophil Gelatinase Lipocalin Levels Are Associated With Increased Oxidative Stress in Hemodialysis Patients. |
| Q38756381 | Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis |
| Q92688849 | Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease |
| Q41184519 | Erythropoietin in chronic renal failure |
| Q52867618 | Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. |
| Q40465508 | Evidence-based recommendations for the clinical use of recombinant human erythropoietin |
| Q80396951 | Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis |
| Q37032277 | High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life |
| Q73566942 | IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 |
| Q79318148 | Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study |
| Q67554391 | Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis |
| Q37155059 | Iron Indices in Patients with Functional Anemia in Chronic Kidney Disease |
| Q46532958 | Iron deficiency in non-dialysis chronic kidney disease |
| Q37042142 | Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. |
| Q41354609 | Iron management in end-stage renal disease |
| Q44900913 | Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin |
| Q47816838 | Iron therapy in the pediatric hemodialysis population |
| Q71865032 | Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents |
| Q41189352 | Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients |
| Q73782135 | Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure |
| Q64064176 | Molecular perspective of iron uptake, related diseases, and treatments |
| Q42666051 | Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects |
| Q42561163 | Poor response to erythropoietin |
| Q45335970 | Recombinant human erythropoietin utilization in Department of Veterans Affairs dialysis units |
| Q70555106 | Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers |
| Q41477431 | Resistance to recombinant erythropoietin in a hemodialysis patient with heterozygous hemoglobinopathy J-Meinung |
| Q73484885 | Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients |
| Q40876012 | Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. |
| Q50120544 | Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis |
| Q41546176 | Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients |
| Q41612091 | Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial |
| Q41080823 | The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states |
| Q80532192 | The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis |
| Q28361138 | The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis |
| Q37767350 | The use of erythropoietin in renal failure |
| Q38066210 | Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm |
| Q69780867 | Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin |
| Q36123635 | Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing |
| Q68254283 | Whole blood superoxide anion generation and efficiency of some erythrocyte antioxidant systems during recombinant human erythropoietin therapy of uremic anemia |
Search more.